Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

259 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of variable-dose treatment with a new U.S. Botulinum Toxin Type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study.
Kane MAC, Brandt F, Rohrich RJ, Narins RS, Monheit GD, Huber MB; Reloxin Investigational Group. Kane MAC, et al. Among authors: brandt f. Plast Reconstr Surg. 2009 Nov;124(5):1619-1629. doi: 10.1097/PRS.0b013e3181b5641b. Plast Reconstr Surg. 2009. PMID: 19584772 Clinical Trial.
A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint.
Hanke CW, Narins RS, Brandt F, Cohen JL, Donofrio LM, Downie J, Heinz M, Harrington L, McDaniel DH, Nestor M, Schlessinger J, Schlöbe A, Taub A, Weiss RA. Hanke CW, et al. Among authors: brandt f. Dermatol Surg. 2013 Jun;39(6):891-9. doi: 10.1111/dsu.12160. Epub 2013 Mar 18. Dermatol Surg. 2013. PMID: 23506308 Clinical Trial.
259 results